STAT5A and acute lymphoblastic leukemia: Furthermore, strategies using chemotherapeutic agents and tyrosine kinase inhibitors combined with STAT5A siRNA should be explored, both in vitro and in animal models, which could potentially improve the efficacy of existing ALL therapies and help circumvent drug resistance.